AVACTA GROUP PLC

Share Issue/Capital Change • Oct 27, 2025

National Storage Mechanism | Additional information

RNS Number : 0074F

Avacta Group PLC

27 October 2025

Avacta Group plc

("Avacta" or "the Group" or "the Company")

Block Listing Six Monthly Return

LONDON AND PHILADELPHIA  - October 27, 2025 Avacta Therapeutics (AIM: AVCT, 'the Company'), a clinical stage biopharmaceutical company developing pre|CISION ®, a tumor-activated oncology delivery platform, today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:

Name of applicant:		Avacta Group plc
Name of scheme:		EMI scheme
Period of return:	From:	28 April 2025		27 October 2025
Balance of unallotted securities under scheme(s) from previous return:		228,380
Plus:    The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		nil
Less:    Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		103,822
Equals:    Balance under scheme(s) not yet issued/allotted at end of period:		124,558

Name of applicant:			Avacta Group plc
Name of scheme:			LTIP/ESOS scheme
Period of return:	From:		28 April 2025		27 October 2025
Balance of unallotted securities under scheme(s):			1,546,375
Plus:    The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):			6,500,000
Less:    Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):			6,862,713
Equals:    Balance under scheme(s) not yet issued/allotted at end of period:			1,183,662
Name of contact:		Brian Hahn, Company Secretary
Telephone number of contact:		+ 44 (0) 1904 217070

Ends-

For further information from Avacta Group plc, please contact:

Avacta Group plc Christina Coughlin, Chief Executive Officer	https://avacta.com/ via ICR Healthcare
Peel Hunt (Nomad and Joint Broker) James Steel / Chris Golden	www.peelhunt.com
Panmure Liberum (Joint Broker) Emma Earl / Will Goode / Mark Rogers Zeus (Joint Broker) James Hornigold / George Duxberry Dominic King	www.panmureliberum.com www.zeuscapital.co.uk
ICR Healthcare (Europe/UK media and investors) Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert	[email protected]
Investor Contact Renee Leck THRUST Strategic Communications	[email protected]
Media Contact Carly Scaduto THRUST Strategic Communications	[email protected]

About pre|CISION®

The key aspect of pre|CISION® is its peptide drug conjugates (PDC) technology.  The combination of the cancer drug and the proprietary cleavable peptide (the PDC) is inert and incapable of entering cells and killing them until the peptide is specifically released within the tumor. The active payload in the pre|CISION® PDC is released when the PDC comes into contact with the common tumor-associated protein, known as fibroblast activation protein (FAP), in the tumor. The release of the payload from the pre|CISION® product directly in the tumor results in higher concentration of the drug at the tumor and lower blood and healthy tissue levels than standard systemic administration, offering the potential to improve efficacy and patient tolerability.

About Avacta -  www.avacta.com

Avacta is a clinical stage life sciences company developing an innovative proprietary drug delivery peptide drug conjugate (PDC) platform, pre|CISION®. The pre|CISION® platform uniquely enables the repurposing of a range of oncology drugs as PDC payloads with the goal to significantly reduce toxicity and side effects for patients by concentrating the drug directly in the tumor.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLRPPGMPUUPAGMM